The Myocardial Protection of HTK Cardioplegic Solution on the Long-Term Ischemic Period In Pediatric Heart Surgery

Cardioplegic reperfusion during a long term ischemic period interrupts cardiac surgery and also increase cellular edema due to repeated administration. We reviewed the clinical experiences on myocardial protection of one single perfusion with histidine-ketoglutarate-tryptophan (HTK) for infants. This retrospective study included 118 infants who underwent open-heart surgery between January 2004 and December 2007. We divided the entire cohort into two groups: In group H (n = 63), myocardial protection was carried out with one single perfusion with HTK solution, and in group S (n = 55) with conventional St. Thomas crystalloid cardioplegia. The duration of cardiopulmonary bypass (CPB) did not differ between these two groups, but the duration of aortic cross-clamping time in group H was significantly shorter than that in group S (p < 0.05). During reperfusion, the spontaneous re-beating rate was higher in group H (p < 0.05). There were no differences in doses of inotropic agent and creatinekinase (CK) values on postoperative day 1 between these two groups, but the level of CK in group H was significantly less than that in group S on postoperative day 2 (p < 0.01). The mortality in group H was lower than in group S (p < 0.05). The HTK group had shorter cross-clamping time and more frequent spontaneous defibrillation than St. Thomas group. We propose that HTK is valid for some complicated cardiac surgeries with long term cross-clamping time.

[1]  L. Gui The Observation of Bretschneider's Cardioplegia Solution on Infants' Immature Myocardial Protection , 2006 .

[2]  K. Tabayashi,et al.  Myocardial protection of the pressure overload hypertrophied heart in human cardiac surgery by acceleration of anaerobic glycolysis. , 2002, Journal of Cardiovascular Surgery.

[3]  D. Salazar,et al.  Clinical impact of histidine-ketoglutarate-tryptophan (HTK) cardioplegic solution on the perioperative period in open heart surgery patients. , 2001, Archives of medical research.

[4]  P. Spieckermann,et al.  Postischemic cardiac function recovery in the isolated rat heart: effects of adenosine deaminase and nucleoside transport inhibition , 2000, Langenbeck's Archives of Surgery.

[5]  J. Maublant,et al.  Cultured neonatal rat cardiomyocytes and 99mTc-sestamibi to assess the direct effects of cardioplegia. , 1998, Cardiovascular surgery.

[6]  N. Ehsani,et al.  Comparison of the Solutions of Bretschneider, St. Thomas’ Hospital and the National Institutes of Health for Cardioplegic Protection during Moderate Hypothermic Arrest , 1998, European Surgical Research.

[7]  T. Kazui,et al.  Comparison of Clinical Outcome Between Histidine‐Triptophan‐Ketoglutalate Solution and Cold Blood Cardioplegic Solution in Mitral Valve Replacement , 1998, Journal of cardiac surgery.

[8]  H. Koyanagi,et al.  Clinical assessment of prolonged myocardial preservation for patients with a severely dilated heart. , 1997, The Annals of thoracic surgery.

[9]  K. Yasuda,et al.  [Comparison of the protective prorerties of St. Thomas', Tyers', and Bretschneider's cardioplegic solutions in the neonatal rabbit heart]. , 1996, [Zasshi] [Journal]. Nihon Kyobu Geka Gakkai.

[10]  A. Chávez-Negrete,et al.  Control of myocardial reperfusion injury with hypertonic-hyperosmotic solution in isolated rabbit heart. , 1995, European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes.

[11]  U. Losert,et al.  Myocardial protection with Bretschneider cardioplegic solution--an evaluation of full oxygenation. , 1994, European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes.

[12]  D. Garcia-Dorado,et al.  Myocardial oedema: a preventable cause of reperfusion injury? , 1993, Cardiovascular research.

[13]  W. Keon,et al.  A comparison of intracellular solutions for donor heart preservation. , 1993, The Journal of thoracic and cardiovascular surgery.

[14]  R. Bolli,et al.  Reperfusion induced injury: manifestations, mechanisms, and clinical relevance. , 1992, Cardiovascular research.

[15]  R. Bolli,et al.  Reperfusion-induced injury manifestations, mechanisms, and clinical relevance. , 1991, Trends in cardiovascular medicine.

[16]  C. Apstein,et al.  Resistance of neonatal myocardium to injury during normothermic and hypothermic ischemic arrest and reperfusion. , 1987, Circulation.

[17]  J. Kresh,et al.  The relative buffering power of cardioplegic solutions. , 1987, Journal of Thoracic and Cardiovascular Surgery.

[18]  K. Stapenhorst,et al.  Intracellular pH measurement during cardiac arrest in ventricular myocardium by Bretschneider's cardioplegic solution HTK and St. Thomas Hospital solution with and without procaine. , 1987, The Thoracic and cardiovascular surgeon.

[19]  H. Scheld,et al.  Ultrastructural study comparing the efficacy of five different methods of intraoperative myocardial protection in the human heart. , 1986, The Journal of thoracic and cardiovascular surgery.

[20]  P. D. del Nido,et al.  The role of cardioplegic solution buffering in myocardial protection. A biochemical and histopathological assessment. , 1985, The Journal of thoracic and cardiovascular surgery.